Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 3/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.44 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 3/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.37 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL8165615 | 0.98 | MGMT (0.44) | MGMTPNPGDADPP4PDPK1 | |
| Benzene SCHEMBL8024450 | 0.97 | MGMT (0.43) | MGMTPNPGDADPP4PDPK1 | |
| SCHEMBL6821773 | 0.86 | PNP (0.45) | MGMTPNPGDADPP4PDPK1 | |
| SCHEMBL28559768 | 0.86 | MGMT (0.41) | MGMTPNPGDADPP4PDPK1 | |
| SCHEMBL453204 | 0.84 | CYP1A2 (0.41) | MGMTPNPGDADPP4PDPK1 | |
| SCHEMBL8843878 | 0.82 | PDE4A (0.43) | MGMTPNPCDK2CDK1CCNB1 | |
| SCHEMBL28627686 | 0.81 | PNP (0.41) | MGMTPNPGDADPP4PDPK1 | |
| Acetic Acid SCHEMBL5323943 | 0.81 | MGMT (0.44) | MGMTPNPGDADPP4PDPK1 | |
| SCHEMBL5694191 | 0.79 | NPC1 (0.51) | MGMTPNPCDK2CDK1CCNB1 | |
| SCHEMBL9710360 | 0.79 | PIN1 (0.68) | MGMTCDK2CDK1CCNB1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114047262-B | Method for separating and measuring easily-hydrolyzed large polar compound | 湖北省宏源药业科技股份有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-114047262-A | Method for separating and measuring easily hydrolyzed large-polarity compound | 湖北省宏源药业科技股份有限公司 | 2022-02-15 | — | — | CN | claimed |
| CN-113735857-A | Acyclovir potential impurity and preparation method thereof | 湖北省宏源药业科技股份有限公司 | 2021-12-03 | — | — | CN | claimed |
| CN-108467396-A | A kind of preparation method of Ganciclovir | 安徽海康药业有限责任公司 | 2018-08-31 | — | — | CN | claimed |
| WO-2006102970-A9 | MODIFIED SHORT INTERFERING RNA | QIAGEN GMBH (DE) | 2016-05-26 | — | — | WO | claimed |
| US-8088752-B2 | Methods for metabolic modulation | VDF FUTURECEUTICALS, INC. (US) | 2012-01-03 | — | — | US | claimed |
| EP-2157182-A2 | Modified short interfering RNA | Qiagen GmbH (DE) | 2010-02-24 | — | — | EP | claimed |
| US-20090197332-A1 | Modified Short Interfering RNA | QIAGEN GMBH (DE) | 2009-08-06 | — | — | US | claimed |
| CN-101475572-A | Chemical synthesis of triacetylganciclovir | XIAOSHUN ZHANG (CN) | 2009-07-08 | — | — | CN | claimed |
| CN-101463034-A | Preparation of triacetylganciclovir | XIAOSHUN ZHANG (CN) | 2009-06-24 | — | — | CN | claimed |
| EP-1453833-A2 | A PROCESS FOR THE PREPARATION OF GANCICLOVIR INTERMEDIATE N2-ACETYL-9-(1,3-DIACETOXY-2-PROPOXYMETHYL) GUANINE | RANBAXY LABORATORIES, LTD. (IN) | 2004-09-08 | — | — | EP | claimed |
| EP-0747389-B1 | 3'-SUBSTITUTED NUCLEOSIDE DERIVATIVES | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-09-10 | — | — | EP | claimed |
| WO-2003033498-A2 | A PROCESS FOR THE TREATMENT OF GANCICLOVIR INTERMEDIATE N2-ACETYL-9-(1, 3-DIACETOXY-2-PROPOXYMETHYL) GUANINE | RANBAXY LABORATORIES LIMITED (IN) | 2003-04-24 | — | — | WO | claimed |
| US-RE38090-E1 | Antitumor activity; useful for treatment and prevention of cancers | Matsuda, Akira (JP) | 2003-04-22 | — | — | US | claimed |
| EP-0763047-B1 | NOVEL METHOD OF PRODUCING NUCLEOSIDES | HOECHST AG (DE) | 2002-01-23 | — | — | EP | claimed |
| WO-1997014709-A1 | ANTISENSE OLIGOMERS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-04-24 | — | — | WO | claimed |
| EP-0747389-A1 | 3'-SUBSTITUTED NUCLEOSIDE DERIVATIVES | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1996-12-11 | — | — | EP | claimed |
| EP-0243670-B1 | PURINE AND PYRIMIDINE COMPOUNDS AND THEIR USE AS ANTI-VIRAL AGENTS | SYNTEX (U.S.A.) INC. (US) | 1992-07-22 | — | — | EP | claimed |
| WO-1992011276-A1 | NOVEL SYNTHESIS OF 2'-'UP' FLUORINATED 2''-DEOXY-ARABINOFURANOSYLPURINES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1992-07-09 | — | — | WO | claimed |
| EP-0243670-A1 | Purine and pyrimidine compounds and their use as anti-viral agents | SYNTEX (U.S.A.) INC. (US) | 1987-11-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197332-A1 | Modified Short Interfering RNA | NSUN2, NSUN3, METTL16 | MGMT 1172/4885PNP 1161/4885GDA 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.